The Plastics & Devices division focuses on the development and manufacturing of drug delivery systems and packaging solutions for the pharmaceutical, biotech, diagnostics, and medical technology industries. R&D activities include the design and engineering of inhalers, insulin pen systems, prefillable syringes, and diagnostic systems. Technologies employed encompass injection molding, extrusion, and advanced assembly processes. This segment addresses a wide range of therapeutic areas, including diabetes, respiratory diseases, and diagnostics. The patient impact is significant, as these devices improve the accuracy and ease of medication delivery. Gerresheimer holds a strong market position due to its broad product portfolio and global manufacturing footprint. Future opportunities lie in the development of smart drug delivery systems and connected health solutions. Regulatory aspects are crucial, with products requiring FDA and other regulatory approvals. Partnerships with pharmaceutical companies are key to this segment's success.

This segment specializes in the production of glass primary packaging for the pharmaceutical and cosmetics industries. R&D efforts are focused on improving glass quality, developing new container designs, and enhancing manufacturing efficiency. Technologies include glass forming, annealing, and surface treatment processes. The segment serves various therapeutic areas, including injectable drugs, ophthalmic solutions, and liquid medications. Patient impact is realized through the safe and reliable containment of medications. Gerresheimer's market position is strengthened by its expertise in glass manufacturing and its ability to meet stringent regulatory requirements. Future growth opportunities include the development of sustainable packaging solutions and the expansion of its product portfolio. Regulatory compliance, including adherence to USP and EP standards, is critical. Partnerships with pharmaceutical companies and cosmetic brands are essential for market access and product development.

The Advanced Technologies division is dedicated to developing smart drug delivery systems, such as micro pumps, for self-administration of medications. R&D activities include the design, prototyping, and testing of micro pumps and related electronic components. Technologies used involve microfluidics, precision engineering, and embedded systems. This segment primarily targets therapeutic areas like Parkinson's disease and heart failure. The patient impact is substantial, as these systems enable precise and controlled drug delivery, improving patient outcomes and quality of life. Gerresheimer's market position is enhanced by its innovative technology and its ability to provide customized solutions. Future opportunities include the integration of sensors and connectivity features. Regulatory aspects are complex, requiring compliance with medical device regulations. Partnerships with pharmaceutical and biotech companies are crucial for clinical trials and commercialization.